Breast Cancer Research and Treatment

, Volume 114, Issue 1, pp 85–96 | Cite as

The effect of thrombospondin-1 on breast cancer metastasis

  • Karen O. Yee
  • Caitlin M. Connolly
  • Mark Duquette
  • Shideh Kazerounian
  • Raymond Washington
  • Jack Lawler
Preclinical Study


Thrombospondin-1 (TSP-1) has been proposed to have both pro-metastatic and anti-metastatic properties. To elucidate its role in breast cancer metastasis, we compared tumor progression in the polyomavirus middle T antigen (Pyt) transgenic mouse and the TSP-1-null Pyt transgenic mouse. We characterized the tumors in these mice at 45, 60 and 90 days of age. Tumor size, areas of necrosis, macrophage infiltration, levels of active and total TGF-β, vessel morphology, and lung and blood metastasis were measured in these mice. Mammary tumors were larger in the TSP-1-null mouse, and vessels were larger, but fewer in number in these tumors. The level of total TGF-β was significantly higher in the Pyt tumors at 90 days of age. Importantly, significantly fewer metastases were observed in the lungs of the TSP-1-null/Pyt mouse. Primary Pyt tumor cells were more migratory than TSP-1-null Pyt tumor cells on collagen. Treatment of Pyt mice with recombinant proteins that contain the type-1 repeats of TSP-1 resulted in decreased primary tumor growth and metastasis. Sequences that are involved in CD36 binding and those required for TGF-β activation mediated the inhibition of primary tumor growth. Thus, TSP-1 in the mammary tumor microenvironment inhibits angiogenesis and tumor growth, but promotes metastasis to the lung in the Pyt transgenic mouse. The ability of TSP-1 to support metastasis correlates with its ability to promote tumor cell migration.


Metastasis Migration Polyomavirus middle T antigen TGF-β Transgenic mouse 



The authors would like to thank fellow lab members Eric Galardi for assistance with the mice and Xuefeng Zhang for helpful discussion on the project. We also would like to thank Ricky Sanchez for sectioning the frozen tumors. Karen Yee was supported by a fellowship from Aid for Cancer Research (Newton, MA). Raymond Washington is supported by a training grant from the National Institute of Health (T32HL007893). This work was supported by grants from the National Institute of Health (CA92644 and HL68003).


  1. 1.
    Chen H, Herndon ME, Lawler J (2000) The cell biology of thrombospondin-1. Matrix Biol 19:597–614PubMedCrossRefGoogle Scholar
  2. 2.
    Lawler J (2002) Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6:1–12PubMedCrossRefGoogle Scholar
  3. 3.
    Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, Watnick RS, Straume O, Akslen LA, Folkman J, Almog N (2006) A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 98:316–325PubMedGoogle Scholar
  4. 4.
    Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA (2003) Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3:219–231PubMedCrossRefGoogle Scholar
  5. 5.
    Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, Hynes RO (2001) Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol 159:1949–1956PubMedGoogle Scholar
  6. 6.
    Volpert OV, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, Shiflett CB, Devlin MK, Conant K, Alani RM (2002) Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2:473–483PubMedCrossRefGoogle Scholar
  7. 7.
    Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF (1999) Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 5:1041–1056PubMedGoogle Scholar
  8. 8.
    Schultz-Cherry S, Lawler J, Murphy-Ullrich JE (1994) The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J Biol Chem 269:26783–26788PubMedGoogle Scholar
  9. 9.
    Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N (1998) Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93:1159–1170PubMedCrossRefGoogle Scholar
  10. 10.
    Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML (2001) Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 98:12485–12490PubMedCrossRefGoogle Scholar
  11. 11.
    Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP (1999) Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 3:147–158PubMedCrossRefGoogle Scholar
  12. 12.
    Bein K, Simons M (2000) Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 275:32167–32173PubMedCrossRefGoogle Scholar
  13. 13.
    Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP (2002) Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 8:349–357PubMedCrossRefGoogle Scholar
  14. 14.
    Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N (2000) Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6:41–48PubMedCrossRefGoogle Scholar
  15. 15.
    Nor JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, Polverini PJ (2000) Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 37:209–218PubMedCrossRefGoogle Scholar
  16. 16.
    Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D’Amato RJ, Kerbel RS (2005) Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7:101–111PubMedGoogle Scholar
  17. 17.
    Rafii DC, Psaila B, Butler J, Jin DK, Lyden D (2008) Regulation of vasculogenesis by platelet-mediated recruitment of bone marrow derived cells. Arterioscler Thromb Vasc Biol 28:217–222PubMedCrossRefGoogle Scholar
  18. 18.
    Magnetto S, Bruno-Bossio G, Voland C, Lecerf J, Lawler J, Delmas P, Silverstein R, Clezardin P (1998) CD36 mediates binding of soluble thrombospondin-1 but not cell adhesion and haptotaxis on immobilized thrombospondin-1. Cell Biochem Funct 16:211–221PubMedCrossRefGoogle Scholar
  19. 19.
    Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP (1997) CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138:707–717PubMedCrossRefGoogle Scholar
  20. 20.
    Urquidi V, Sloan D, Kawai K, Agarwal D, Woodman AC, Tarin D, Goodison S (2002) Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res 8:61–74PubMedGoogle Scholar
  21. 21.
    Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS (1994) Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 54:6504–6511PubMedGoogle Scholar
  22. 22.
    Yabkowitz R, Mansfield PJ, Dixit VM, Suchard SJ (1993) Motility of human carcinoma cells in response to thrombospondin: relationship to metastatic potential and thrombospondin structural domains. Cancer Res 53:378–387PubMedGoogle Scholar
  23. 23.
    Adams JC, Lawler J (2004) The thrombospondins. Int J Biochem Cell Biol 36:961–968PubMedCrossRefGoogle Scholar
  24. 24.
    Albo D, Rothman VL, Roberts DD, Tuszynski GP (2000) Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br J Cancer 83:298–306PubMedCrossRefGoogle Scholar
  25. 25.
    Albo D, Berger DH, Wang TN, Hu X, Rothman V, Tuszynski GP (1997) Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. Surgery 122:493–499; discussion 499–500PubMedCrossRefGoogle Scholar
  26. 26.
    Wang TN, Qian X, Granick MS, Solomon MP, Rothman VL, Berger DH, Tuszynski GP (1996) Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res 63:39–43PubMedCrossRefGoogle Scholar
  27. 27.
    Albo D, Berger DH, Tuszynski GP (1998) The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion. J Surg Res 76:86–90PubMedCrossRefGoogle Scholar
  28. 28.
    Albo D, Arnoletti JP, Castiglioni A, Granick MS, Solomon MP, Rothman VL, Tuszynski GP (1994) Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro. Biochem Biophys Res Commun 203:857–865PubMedCrossRefGoogle Scholar
  29. 29.
    Wang TN, Qian XH, Granick MS, Solomon MP, Rothman VL, Tuszynski GP (1995) The effect of thrombospondin on oral squamous carcinoma cell invasion of collagen. Am J Surg 170:502–505PubMedCrossRefGoogle Scholar
  30. 30.
    Arnoletti JP, Albo D, Granick MS, Solomon MP, Castiglioni A, Rothman VL, Tuszynski GP (1995) Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer 76:998–1005PubMedCrossRefGoogle Scholar
  31. 31.
    Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12:954–961PubMedGoogle Scholar
  32. 32.
    Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, Nicholson B, Cardiff RD, MacLeod CL (2001) Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 61:8298–8305PubMedGoogle Scholar
  33. 33.
    Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163:2113–2126PubMedGoogle Scholar
  34. 34.
    Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, Hynes RO (1998) Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 101:982–992PubMedCrossRefGoogle Scholar
  35. 35.
    Miao WM, Seng WL, Duquette M, Lawler P, Laus C, Lawler J (2001) Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res 61:7830–7839PubMedGoogle Scholar
  36. 36.
    Yee KO, Streit M, Hawighorst T, Detmar M, Lawler J (2004) Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am J Pathol 165:541–552PubMedGoogle Scholar
  37. 37.
    Inoue T, Plieth D, Venkov CD, Xu C, Neilson EG (2005) Antibodies against macrophages that overlap in specificity with fibroblasts. Kidney Int 67:2488–2493PubMedCrossRefGoogle Scholar
  38. 38.
    Lanari C, Luthy I, Lamb CA, Fabris V, Pagano E, Helguero LA, Sanjuan N, Merani S, Molinolo A (2001) Five novel hormone-responsive cell lines derived frommurine mamnary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res 61:293–302PubMedGoogle Scholar
  39. 39.
    Lin EY, Pollard JW (2004) Macrophages: modulators of breast cancer progression. Novartis Found Symp 256:158–168; discussion 168–172, 259–169PubMedCrossRefGoogle Scholar
  40. 40.
    Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66:11238–11246PubMedCrossRefGoogle Scholar
  41. 41.
    Lin EY, Pollard JW (2007) Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 67:5064–5066PubMedCrossRefGoogle Scholar
  42. 42.
    Yee KO, Connolly CM, Pines M, Lawler J (2006) Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism. Cancer Biol Ther 5:218–224PubMedGoogle Scholar
  43. 43.
    Zhang X, Lawler J (2007) Thrombospondin-based antiangiogenic therapy. Microvasc Res 74:90–99PubMedCrossRefGoogle Scholar
  44. 44.
    Anderson JC, Grammer JR, Wang W, Nabors LB, Henkin J, Stewart JE Jr, Gladson CL (2007) ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther 6:454–462PubMedCrossRefGoogle Scholar
  45. 45.
    Isenberg JS, Yu C, Roberts DD (2008) Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem Pharmacol 75:875–882PubMedCrossRefGoogle Scholar
  46. 46.
    Harpel JG, Schultz-Cherry S, Murphy-Ullrich JE, Rifkin DB (2001) Tamoxifen and estrogen effects on TGF-beta formation: role of thrombospondin-1, alphavbeta3, and integrin-associated protein. Biochem Biophys Res Commun 284:11–14PubMedCrossRefGoogle Scholar
  47. 47.
    Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE (1999) The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem 274:13586–13593PubMedCrossRefGoogle Scholar
  48. 48.
    Ribeiro SM, Schultz-Cherry S, Murphy-Ullrich JE (1995) Heparin-binding vitronectin up-regulates latent TGF-beta production by bovine aortic endothelial cells. J Cell Sci 108(Pt 4):1553–1561PubMedGoogle Scholar
  49. 49.
    Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE (1995) Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem 270:7304–7310PubMedCrossRefGoogle Scholar
  50. 50.
    Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE (1994) Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem 269:26775–26782PubMedGoogle Scholar
  51. 51.
    Schultz-Cherry S, Murphy-Ullrich JE (1993) Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J Cell Biol 122:923–932PubMedCrossRefGoogle Scholar
  52. 52.
    Murphy-Ullrich JE, Schultz-Cherry S, Hook M (1992) Transforming growth factor-beta complexes with thrombospondin. Mol Biol Cell 3:181–188PubMedGoogle Scholar
  53. 53.
    Tan K, Duquette M, Liu JH, Dong Y, Zhang R, Joachimiak A, Lawler J, Wang JH (2002) Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. J Cell Biol 159:373–382PubMedCrossRefGoogle Scholar
  54. 54.
    Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J, Bouck NP (1999) Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 55:332–338PubMedGoogle Scholar
  55. 55.
    Simantov R, Silverstein RL (2003) CD36: a critical anti-angiogenic receptor. Front Biosci 8:s874–s882PubMedCrossRefGoogle Scholar
  56. 56.
    Nakagawa T, Martinez SR, Goto Y, Koyanagi K, Kitago M, Shingai T, Elashoff DA, Ye X, Singer FR, Giuliano AE, Hoon DS (2007) Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res 13:4105–4110PubMedCrossRefGoogle Scholar
  57. 57.
    Alix-Panabieres C, Muller V, Pantel K (2007) Current status in human breast cancer micrometastasis. Curr Opin Oncol 19:558–563PubMedGoogle Scholar
  58. 58.
    Lang JE, Hall CS, Singh B, Lucci A (2007) Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application? Expert Rev Anticancer Ther 7:1463–1472PubMedCrossRefGoogle Scholar
  59. 59.
    Bornstein P, Sage EH (2002) Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 14:608–616PubMedCrossRefGoogle Scholar
  60. 60.
    Orend G, Chiquet-Ehrismann R (2006) Tenascin-C induced signaling in cancer. Cancer Lett 244:143–163PubMedCrossRefGoogle Scholar
  61. 61.
    Tuck AB, Chambers AF, Allan AL (2007) Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 102:859–868PubMedCrossRefGoogle Scholar
  62. 62.
    Moura R, Tjwa M, Vandervoort P, Cludts K, Hoylaerts MF (2007) Thrombospondin-1 activates medial smooth muscle cells and triggers neointima formation upon mouse carotid artery ligation. Arterioscler Thromb Vasc Biol 27:2163–2169PubMedCrossRefGoogle Scholar
  63. 63.
    Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA, Gasic GJ (1987) Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res 47:4130–4133PubMedGoogle Scholar
  64. 64.
    Wang TN, Qian XH, Granick MS, Solomon MP, Rothman VL, Berger DH, Tuszynski GP (1996) Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor. Surgery 120:449–454PubMedCrossRefGoogle Scholar
  65. 65.
    Zhang X, Galardi E, Duquette M, Delic M, Lawler J, Parangi S (2005) Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin Cancer Res 11:2337–2344PubMedCrossRefGoogle Scholar
  66. 66.
    Byrne GJ, Hayden KE, McDowell G, Lang H, Kirwan CC, Tetlow L, Kumar S, Bundred NJ (2007) Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. Int J Oncol 31:1127–1132PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Karen O. Yee
    • 1
  • Caitlin M. Connolly
    • 1
  • Mark Duquette
    • 1
  • Shideh Kazerounian
    • 1
  • Raymond Washington
    • 1
  • Jack Lawler
    • 1
  1. 1.The Division of Cancer Biology and Angiogenesis, Department of PathologyBeth Israel Deaconess Medical Center and Harvard Medical SchoolBostonUSA

Personalised recommendations